Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENTERPRISE vedolizumab dosing study in perianal fistulizing Crohn's disease
NL-OMON45760Phase 4Active, not recruiting
- Sponsor
- Takeda
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vedolizumab in Crohn's disease (2 arms), sponsored by Takeda. Primary endpoint: Fistula response at Week 30. Started Dec 2016; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON45760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45760.